i think they are also a lot closer to commercializing some of their other products in the portfolio than the rest of the market thinks.
however, the burette and autoflush are the most imminent avenues to potential elephant deals so they are continuing with that story.
i.e they don't want to confuse the market by giving updates about the entire product range when everyone is hungry for some real leverage from the burette and autoflush products.
should hear news about qld health and rpa hospital trial in next few weeks or early november. any success her could have significant gains in sp
ALT Price at posting:
2.1¢ Sentiment: Buy Disclosure: Held